Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients — Oligo-PRESTO  

Oligometastatic Hormone Sensitive Prostate Cancer Clinical Trial

Official title: Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial

Status Recruiting

Clinical Trial Summary

INDICATION: Oligometastatic hormone-sensitive prostate cancer patients. METHODOLOGY: Open label, double arm, randomized 1:1, multicenter phase III study. PRIMARY OBJECTIVE: To assess the efficacy of ablative radiotherapy (SBRT applied to all oligometastases) administered to all gross tumor sites (metastases and prostate if applicable), in oligometastatic hormone-sensitive prostate cancer patients.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hypersensitivity
• Oligometastatic Hormone Sensitive Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT04115007
• Study type: Interventional
• Source: UNICANCER
• Contact: Vanessa SCHARTNER
• Phone: +33 6 25 15 59 63
• Email: v-schartner@unicancer.fr
• Status: Recruiting
• Phase: Phase 3
• Start date: June 23, 2020
• Completion date: February 28, 2031